- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07491952
Technique d'Aspiration Continue Double Avec Système Zoom pour l'Accident Vasculaire Cérébral (ADAPT 2 0)
Évaluation clinique de la technique d'aspiration double continue avec le système Zoom pour les accidents vasculaires cérébraux (ADAPT 2.0)
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Pojai Phattanagosai
- Numéro de téléphone: 650-740-7703
- E-mail: pphattanagosai@Imperativecare.com
Sauvegarde des contacts de l'étude
- Nom: Emma Pham
- Numéro de téléphone: 408-421-7684
- E-mail: epham@imperativecare.com
Lieux d'étude
-
-
Alabama
-
Huntsville, Alabama, États-Unis, 35801
- Recrutement
- Huntsville Hospital
-
Contact:
- Farrar Hickey
-
Chercheur principal:
- R. Dana Tomalty, MD
-
-
California
-
Walnut Creek, California, États-Unis, 94598
- Recrutement
- John Muir Health
-
Chercheur principal:
- Benjamin Yim, MD
-
Contact:
- Melenie Aaron
-
-
Florida
-
Tampa, Florida, États-Unis, 33606
- Recrutement
- University of South Florida
-
Chercheur principal:
- Maxim Mokin, MD
-
Contact:
- Kilaun Robinson
-
-
Georgia
-
Marietta, Georgia, États-Unis, 30060
- Recrutement
- Wellstar Kennestone Hospital
-
Contact:
- Autumn Lee
-
Chercheur principal:
- Ahmad Khaldi, MD
-
-
Louisiana
-
Lafayette, Louisiana, États-Unis, 70503
- Recrutement
- Ochsner Clinic Foundation (Lafayette)
-
Chercheur principal:
- Shail Thanki, MD
-
New Orleans, Louisiana, États-Unis, 70121
- Recrutement
- Ochsner Clinic Foundation
-
Chercheur principal:
- James Milburn, MD
-
Contact:
- Jessica Henry
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21201
- Recrutement
- University of Maryland
-
Chercheur principal:
- Jacob Cherian, MD
-
Contact:
- Katie Henry
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55407
- Recrutement
- Allina Health
-
Contact:
- Emeryth Beloy
-
Chercheur principal:
- Collin Torok, MD
-
-
New York
-
Albany, New York, États-Unis, 12208
- Recrutement
- Albany Medical College
-
Chercheur principal:
- Alexandra Paul, MD
-
Contact:
- Chelsey Large
-
Buffalo, New York, États-Unis, 14203
- Recrutement
- University at Buffalo Neurosurgery
-
Chercheur principal:
- Jason Davies, MD
-
Contact:
- Ellen Carl
-
New York, New York, États-Unis, 10065
- Recrutement
- Weill Cornell Medicine
-
Contact:
- Hanah Hwang
-
Chercheur principal:
- Amol Mehta, MD
-
New York, New York, États-Unis, 10029
- Recrutement
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Kevin Buttet
-
Chercheur principal:
- Michael T Caton, MD
-
Syracuse, New York, États-Unis, 13210
- Recrutement
- SUNY Upstate Medical Center
-
Contact:
- Saptarshi Prachi
-
Chercheur principal:
- Haydn Hoffman, MD
-
The Bronx, New York, États-Unis, 10467
- Recrutement
- Montefiore Medical Center
-
Contact:
- Genesis Liriano
-
Chercheur principal:
- Amanda Baker, MD
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45220
- Recrutement
- TriHealth Good Samaritan Hospital
-
Chercheur principal:
- Andrew Ringer, MD
-
Contact:
- Mehnaaz Ali
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Recrutement
- University of Oklahoma, Health Science Center
-
Chercheur principal:
- Hakeem Shakir, MD
-
Contact:
- Sanaa Hameed
-
-
South Carolina
-
Greenville, South Carolina, États-Unis, 29605
- Recrutement
- Prisma Health - Upstate
-
Contact:
- Shawn Manos
-
Chercheur principal:
- Jan Vargas Machaj, MD
-
-
Tennessee
-
Knoxville, Tennessee, États-Unis, 37902
- Recrutement
- Fort Sanders Regional Medical Center
-
Contact:
- Cameron Carter
-
Chercheur principal:
- Robert Hixson, MD
-
Memphis, Tennessee, États-Unis, 38120
- Recrutement
- Semmes Murphey Foundation
-
Chercheur principal:
- Lucas Elijovich, MD
-
Contact:
- Wendell Barnett
-
-
Texas
-
Kingwood, Texas, États-Unis, 77339
- Recrutement
- HCA Houston Healthcare Kingwood
-
Chercheur principal:
- Mohamad Ezzeldin, MD
-
Contact:
- Swathi Potla
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- Methodist Healthcare System of San Antonio
-
Contact:
- Samantha Franklin
-
Chercheur principal:
- Lee Birnbaum, MD
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- University of Texas Science Health Center at San Antonio
-
Chercheur principal:
- Justin Mascitelli, MD
-
Contact:
- Athena Lazaris-Conner
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Recrutement
- University of Utah
-
Contact:
- Andrew Grandemange
-
Chercheur principal:
- Robert Rennert, MD
-
-
Virginia
-
Falls Church, Virginia, États-Unis, 22042
- Recrutement
- Inova Fairfax Medical Campus
-
Contact:
- Lauren Monroe
-
Chercheur principal:
- James McEachern, MD
-
-
Washington
-
Spokane, Washington, États-Unis, 99204
- Recrutement
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contact:
- Kyle Kramer
-
Chercheur principal:
- Christopher Zylak, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.
La description
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
- Pre-stroke mRS 0-2
- Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use
Exclusion Criteria:
- Subjects with a life expectancy of less than 6 months
- Female subject who is known to be pregnant at time of admission
- Any intracranial hemorrhage in the qualifying head CT or MRI
- Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
- Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)
The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets. |
Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
Délai: End of procedure
|
mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
End of procedure
|
|
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
Délai: End of procedure
|
Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator |
End of procedure
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
Délai: Intraprocedural
|
The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique. mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
Délai: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs |
Intraprocedural
|
|
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
Délai: Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs |
Intraprocedural
|
|
Rate of rescue therapy
Délai: Intraprocedural
|
Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c. |
Intraprocedural
|
|
Rate of functional independence (mRS 0-2) at 90 days
Délai: 90 days post-procedure
|
Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome |
90 days post-procedure
|
|
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
Délai: Intraprocedural
|
Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
Délai: 24-hour post-procedure
|
Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria |
24-hour post-procedure
|
|
90-day all-cause mortality
Délai: 90 days post-procedure
|
Rate of all-cause mortality through 90 days post-procedure |
90 days post-procedure
|
|
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
Délai: Intraprocedural
|
Independently adjudicated rate of Serious Adverse Events related to study device |
Intraprocedural
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: David Fiorella, MD, Stony Brook University Hospital
- Chercheur principal: Shahram Majidi, MD, Icahn School of Medicine at Mount Sinai
- Chercheur principal: Justin Masciteli, MD, The University of Texas Health Science Center at San Antonio
- Chercheur principal: Maxim Mokin, MD, University of South Florida
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- AVC ischémique
- Accident vasculaire cérébral
- Procédures chirurgicales, opératoires
- Procédures chirurgicales vasculaires
- Procédures chirurgicales cardiovasculaires
- Thrombectomie
Autres numéros d'identification d'étude
- ICI-2025-003
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .